QualityStocks.net News – Cell Genesys Inc. (CEGE) Sees Positive Cancer Test Results; Shares Jump 4%

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

We would like to highlight Cell Genesys, Inc. (NASDAQ: CEGE). The company is a biotechnology company focused on the development and commercialization of biological therapies for patients with cancer. Its clinical stage cancer programs involve cell- or viral-based products that have been modified to impart disease-fighting characteristics that are not found in conventional chemotherapeutic agents. The Company’s program is GVAX cancer immunotherapy program.

In the Company’s news today,

Cell Genesys Inc. (CEGE) said Friday its GVAX immunotherapy treatment for recurrent prostate cancer did well in early stage clinical tests. Shares of the San Francisco, Calif.-based company were up nearly 4% to a high of $3.25 during late-day trading.

Data from the trial, which enrolled 19 patients, indicate that GVAX helped 79% of the patients boost antibodies. In addition, the drug was generally well tolerated, with the most common side effects being injection-site reactions in most patients and mild flu-like symptoms in some patients, according to Cell Genesys.

“We are now planning a larger randomized trial to further examine the potential application of GVAX immunotherapy in this patient population and also look forward to learning more from a study currently under way that is evaluating the product in combination with docetaxel as a preoperative therapy in men with high-risk prostate cancer,” said Robert J. Dow, MBChB, Senior Vice President of Medical Affairs and Chief Medical Officer of Cell Genesys.

Results of the trial were to be presented at the annual meeting of the Tumor Vaccine and Cell Therapy Working Group being held in San Diego, California, in conjunction with the American Association for Cancer Research (AACR) annual meeting.

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net